Compare KYIV & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYIV | ARQT |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 2025 | 2020 |
| Metric | KYIV | ARQT |
|---|---|---|
| Price | $12.88 | $27.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $18.87 | ★ $40.38 |
| AVG Volume (30 Days) | 590.4K | ★ 2.5M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $16.85 | $44.19 |
| Revenue Next Year | $7.95 | $29.31 |
| P/E Ratio | ★ N/A | $290.56 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $9.29 | $19.30 |
| 52 Week High | $16.55 | $34.80 |
| Indicator | KYIV | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 43.74 |
| Support Level | $11.25 | $22.93 |
| Resistance Level | $14.14 | $28.54 |
| Average True Range (ATR) | 0.49 | 1.51 |
| MACD | -0.01 | -0.79 |
| Stochastic Oscillator | 17.29 | 20.53 |
Kyivstar Group Ltd is a telecommunications and digital holding company that operates Ukraine provider of mobile communication and broadband services. The company offers a wide range of connectivity and digital services, including mobile and fixed-line voice and data, ride-hailing, e-health, digital TV, and enterprise solutions such as big data, cloud, and cybersecurity. It operates through two main segments: Telecommunications and Digital. The Telecommunications segment, which generates the majority of revenue, includes service revenue from mobile and fixed connectivity services provided to both individual and corporate customers. The Digital segment comprises revenue from proprietary digital platforms and services.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.